Assessing Repeatability and Intra-individual Variability in [O15]H2O-PET Myocardial Perfusion Imaging
NCT ID: NCT06356857
Last Updated: 2025-04-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
20 participants
OBSERVATIONAL
2024-04-15
2026-03-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Myocardial Blood Flow by 15O Water PET
NCT01805193
Myocardial Perfusion Imaging by Combined 15O-H2O PET and MR
NCT04940247
Comparison of Differencens in VO2-max, Perfusion of the Heart and Brain and Cognitive Performance Between Patients with Type 2 Diabetes and Healthy Age Matched Controls.
NCT06628297
Cardiac Magnetic Resonance Assessment for Heart Failure With Preserved Ejection Fraction
NCT04063579
Comparison of Quantitative MRI Perfusion Methods With Quantitative PET Perfusion Imaging
NCT02608944
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
With advancements in scanner and software technology, it is now possible to accurately quantify both global and regional MBF in clinical PET-MPI studies. Reduced stress MBF or MFR, as determined by \[O15\]H2O-PET-MPI, is a reliable indicator for detecting hemodynamically significant coronary artery stenosis. Additionally, MBF and MFR offer valuable prognostic insights into mortality and the risk of myocardial infarction. Clinical experience suggests that implementing \[O15\]H2O-PET-MPI for coronary artery disease evaluation is not only feasible but also aids in making informed decisions regarding revascularization.
This study wish to assess the reproducibility of baseline and hyperemic myocardial blood flow as well as myocardial blood flow reserve measurements with \[O15\]H2O-PET-MPI.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
re-pet participant
Participant are enrolled for a second pet-scan which will be compared with the initial scan.
Myocardial perfusion imaging (MPI) using [O15]H2O-PET-CT
Re-scan for comparison with initial scan
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Myocardial perfusion imaging (MPI) using [O15]H2O-PET-CT
Re-scan for comparison with initial scan
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing to repeat the \[O15\]H2O-PET-MPI
* Normal left ventricular ejection fraction (EF \> 45), as assessed from recent (max 1 year old) echocardiography description in medical journal.
Exclusion Criteria
* History of myocardial infarction
* Regional perfusion deficits on the primary \[O15\]H2O-PET-MPI clinically suspected as a sign of significant coronary stenosis.
* Unstable angina
* Severe Chronic Obstructive Pulmonary Disease (COPD)
* Severe asthma
* Claustrophobia
* Acute illness
* Significant language barrier, estimated by the investigator not being able to understand the study information sufficiently.
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peter Hovind
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Peter Hovind
Head of department, Department of Clinical Physiology and Nuclear Medicine and PET
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Hovind, MD, Phd.
Role: STUDY_CHAIR
Bispebjerg hospital, capitol region Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bispebjerg Hospital
Copenhagen, RegionH, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-23070312
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.